AP286A - Physical form of an indolyl sulphonamide, processes for preparing it and pharmaceutical compositions containing it. - Google Patents

Physical form of an indolyl sulphonamide, processes for preparing it and pharmaceutical compositions containing it. Download PDF

Info

Publication number
AP286A
AP286A APAP/P/1991/000341A AP9100341A AP286A AP 286 A AP286 A AP 286A AP 9100341 A AP9100341 A AP 9100341A AP 286 A AP286 A AP 286A
Authority
AP
ARIPO
Prior art keywords
vhich
indol
amino
physical
physical form
Prior art date
Application number
APAP/P/1991/000341A
Other languages
English (en)
Other versions
AP9100341A0 (en
Inventor
Martin Paul Edwards
John David Sherwood
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AP9100341A0 publication Critical patent/AP9100341A0/xx
Application granted granted Critical
Publication of AP286A publication Critical patent/AP286A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1991/000341A 1990-12-12 1991-12-11 Physical form of an indolyl sulphonamide, processes for preparing it and pharmaceutical compositions containing it. AP286A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027018A GB9027018D0 (en) 1990-12-12 1990-12-12 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
AP9100341A0 AP9100341A0 (en) 1992-01-31
AP286A true AP286A (en) 1993-09-26

Family

ID=10686919

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1991/000341A AP286A (en) 1990-12-12 1991-12-11 Physical form of an indolyl sulphonamide, processes for preparing it and pharmaceutical compositions containing it.

Country Status (28)

Country Link
US (1) US5294636A (enExample)
EP (1) EP0490649B1 (enExample)
JP (1) JP2650807B2 (enExample)
KR (1) KR100194479B1 (enExample)
CN (2) CN1032469C (enExample)
AP (1) AP286A (enExample)
AT (1) ATE145199T1 (enExample)
AU (1) AU656344B2 (enExample)
CA (1) CA2056067C (enExample)
CZ (1) CZ288151B6 (enExample)
DE (1) DE69123123T2 (enExample)
DK (1) DK0490649T3 (enExample)
ES (1) ES2094797T3 (enExample)
FI (1) FI101296B1 (enExample)
GB (2) GB9027018D0 (enExample)
GR (1) GR3021605T3 (enExample)
HK (1) HK81497A (enExample)
HU (2) HU213109B (enExample)
IE (1) IE914316A1 (enExample)
IL (1) IL100090A (enExample)
MX (1) MX9102475A (enExample)
MY (1) MY108629A (enExample)
NZ (1) NZ240940A (enExample)
PH (1) PH30041A (enExample)
RU (1) RU2107682C1 (enExample)
SK (1) SK279018B6 (enExample)
TW (1) TW222264B (enExample)
ZA (1) ZA919772B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0455596T3 (da) * 1990-05-04 1994-11-28 Ciba Geigy Ag Substituerede indoler
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3732508B2 (ja) * 1993-10-01 2006-01-05 アストラ・アクチエボラーグ 粉末状薬剤の製造方法
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090191183A1 (en) * 2007-07-30 2009-07-30 Auspex Pharmaceuticals, Inc. Substituted indoles
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CA3052071A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
JP2024521736A (ja) 2021-05-19 2024-06-04 クエルシス ファーマ エージー 筋萎縮性側索硬化症の治療に使用するためのケルセチン含有組成物
US20250275936A1 (en) 2022-05-06 2025-09-04 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONE *

Also Published As

Publication number Publication date
TW222264B (enExample) 1994-04-11
PH30041A (en) 1996-11-08
GB9126353D0 (en) 1992-02-12
SK279018B6 (sk) 1998-05-06
AU656344B2 (en) 1995-02-02
KR100194479B1 (ko) 1999-06-15
AU8899591A (en) 1992-06-18
NZ240940A (en) 1994-05-26
GR3021605T3 (en) 1997-02-28
CA2056067C (en) 2001-09-04
IL100090A (en) 1996-09-12
US5294636A (en) 1994-03-15
DE69123123D1 (de) 1996-12-19
MY108629A (en) 1996-10-31
ATE145199T1 (de) 1996-11-15
JP2650807B2 (ja) 1997-09-10
HU211125A9 (en) 1995-10-30
DE69123123T2 (de) 1997-03-06
GB9027018D0 (en) 1991-01-30
CN1063100A (zh) 1992-07-29
CN1074411C (zh) 2001-11-07
DK0490649T3 (da) 1997-04-21
ES2094797T3 (es) 1997-02-01
KR920012031A (ko) 1992-07-25
HU913863D0 (en) 1992-02-28
IE914316A1 (en) 1992-06-17
FI915825L (fi) 1992-06-13
FI101296B (fi) 1998-05-29
GB2250743B (en) 1995-02-15
CZ288151B6 (en) 2001-05-16
MX9102475A (es) 1992-06-01
CN1032469C (zh) 1996-08-07
CA2056067A1 (en) 1992-06-13
AP9100341A0 (en) 1992-01-31
JPH04266872A (ja) 1992-09-22
FI915825A0 (fi) 1991-12-11
HK81497A (en) 1997-06-27
CN1148491A (zh) 1997-04-30
GB2250743A (en) 1992-06-17
HUT60717A (en) 1992-10-28
RU2107682C1 (ru) 1998-03-27
IL100090A0 (en) 1992-08-18
CS375891A3 (en) 1992-06-17
EP0490649B1 (en) 1996-11-13
EP0490649A1 (en) 1992-06-17
ZA919772B (en) 1992-09-30
HU213109B (en) 1997-02-28
FI101296B1 (fi) 1998-05-29

Similar Documents

Publication Publication Date Title
AP286A (en) Physical form of an indolyl sulphonamide, processes for preparing it and pharmaceutical compositions containing it.
JP2585495B2 (ja) 医薬品
EP3159336A1 (en) Crystal of allisartan isoproxil, preparation method therefor and pharmaceutical composition containing same
NO179248B (no) Fysikalsk form av N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetylÅ-3-metoksybenzoylÅ-2-metylbenzensulfonamid og fremgangsmåte for fremstilling derav
WO2024230602A1 (zh) 毒蕈碱拮抗剂的晶型及其制备方法和用途
FI106021B (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
HK1233247B (zh) 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物
PT100507B (pt) Nova forma fisica de derivados de amidas heterociclicos, processo para a sua preparacao e composicoes farmaceuticas que os contem